Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the
clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed
to be ineligible for chemotherapy per Investigator assessment. Patients will be enrolled into
2 cohorts according to radiotherapy pretreatment dose (Cohort A: standard radiation therapy
[60 gray (Gy) ± 10% or hypofractionated bioequivalent dose (BED)]; Cohort B: palliative
radiation therapy [40 to < 54 Gy or hypofractionated BED]).